消息面上，药捷安康今日午间发布称公告，公司交易价格及成交量近期出现异常变动。董事会确认，概 不知悉导致股份出现该等股价及成交量异常变动之任何原因；或任何须予公布以避免股份出现虚假市场 之资料；或根据上市规则须予披露之任何内幕消息。董事会亦确认，本集团之业务营运维持正常，且本 集团之业务营运及财务状况并无重大变动。本公司股东及潜在投资者于买卖本公司证券时务请审慎行 事。 药捷安康-B(02617)突现跳水，午后低见320港元，较日内高点679.5港元已跌超50%。截至发稿，跌 16.77%，报345.4港元，成交额28.79亿港元。 值得注意的是，上交所、深交所近日发布公告，药捷安康被调入港股通标的名单，自9月8日起生效。数 据显示，入通后北水资金连续加仓药捷安康，9月12日、9月15日，北水资金分别加仓药捷安康1.8亿、 1.42亿港元。该股今日盘中高见679.5港元，入通以来最大累计涨幅已接近10倍。 ...

消息面上，药捷安康今日午间发布称公告，公司交易价格及成交量近期出现异常变动。董事会确认，概 不知悉导致股份出现该等股价及成交量异常变动之任何原因；或任何须予公布以避免股份出现虚假市场 之资料；或根据上市规则须予披露之任何内幕消息。董事会亦确认，本集团之业务营运维持正常，且本 集团之业务营运及财务状况并无重大变动。本公司股东及潜在投资者于买卖本公司证券时务请审慎行 事。 智通财经APP获悉，药捷安康-B(02617)突现跳水，午后低见320港元，较日内高点679.5港元已跌超 50%。截至发稿，跌16.77%，报345.4港元，成交额28.79亿港元。 值得注意的是，上交所、深交所近日发布公告，药捷安康被调入港股通标的名单，自9月8日起生效。数 据显示，入通后北水资金连续加仓药捷安康，9月12日、9月15日，北水资金分别加仓药捷安康1.8亿、 1.42亿港元。该股今日盘中高见679.5港元，入通以来最大累计涨幅已接近10倍。 ...

（文章来源：每日经济新闻） 每经AI快讯，9月16日，药捷安康-B涨幅收窄至20%以内，早盘一度涨近60%。 ...

此前已经连续大涨的药捷安康-B（02617.HK），今日（9月16日）再度拉涨，其股价一度涨至679.5港 元，涨幅超过50%。 不过在今日午后，药捷安康-B发布了股价及成交量异动的公告称，公司董事会注意到，公司股份价格及 成交量近期出现异动并确认不知道该异动发生的原因，公司的业务运营维持正常。 Transl hera 药捷安康 TransThera Sciences (Nanjing), Inc. 藥捷安康(南京)科技股份有限公司 (於中華人民共和國註冊成立的股份有限公司) (股份代號:2617) 自願性公告 股價及成交量的異常變動 本公告由藥捷安康(南京)科技股份有限公司(「本公司」,連同其附屬公司統稱「本 集團」)自願刊發。 本公司董事會(「董事會」注意到,本公司股份([股份]之交易價格及成交量近 期出現異常變動。經就本公司作出在有關情況下屬合理的一切查詢後,董事會確 認,概不知悉(i)導致股份出現該等股價及成交量異常變動之任何原因;或(ii)任何 須子公佈以避免股份出現虚假市場之資料;或(iii)根據上市規則第13.09(2)條及證 券及期貨條例(香港法例第571章)第XIVA部須予披露之任何内幕消息 ...

董事会亦确认，集团的业务营运维持正常，且集团的业务营运及财务状况并无重大变动。 药捷安康-B(02617)发布公告，公司股份的交易价格及成交量近期出现异常变动。经就公司作出在有关 情况下属合理的一切查询后，董事会确认，概不知悉(i)导致股份出现该等股价及成交量异常变动的任何 原因;或(ii)任何须予公布以避免股份出现虚假市场的资料;或(iii)根据上市规则第13.09(2)条及证券及期货 条例(香港法例第571章)第XIVA部须予披露的任何内幕消息。 ...

智通财经APP讯，药捷安康-B(02617)发布公告，公司股份的交易价格及成交量近期出现异常变动。经就 公司作出在有关情况下属合理的一切查询后，董事会确认，概不知悉(i)导致股份出现该等股价及成交量 异常变动的任何原因;或(ii)任何须予公布以避免股份出现虚假市场的资料;或(iii)根据上市规则第13.09(2) 条及证券及期货条例(香港法例第571章)第XIVA部须予披露的任何内幕消息。 董事会亦确认，集团的业务营运维持正常，且集团的业务营运及财务状况并无重大变动。 ...

Group 1 - The Hang Seng Index rose by 0.07%, gaining 19 points to close at 26,465 points, while the Hang Seng Tech Index increased by 0.39% [1] - The early trading volume in Hong Kong stocks reached 160.2 billion HKD [1] Group 2 - New pharmaceutical stocks in the Hong Kong Stock Connect saw significant gains, with ZhiJie AnKang-B (02617) surging over 49%, reaching a market capitalization of over 240 billion HKD; BaiZe Medical (02609) rose over 76%; and TongYuanKang Pharmaceutical-B (02410) increased by over 36% [1] - Fosen Pharmaceutical (01652) experienced a dramatic rise of over 410%, closing at 1.35 HKD, up 297%, following the approval of Metformin and Ertugliflozin tablets [2] - Shanghai Fudan (01385) increased by 5.87%, with the company well-prepared for supply chain disruptions, and Morgan Stanley noted limited impact on demand [2] - SF Express (09699) rose over 6% as its "SoFast" service officially launched in Macau, with Daiwa optimistic about the company's revenue growth prospects [2] - Valiant Bio-B (09887) increased by over 13%, with its core product LBL-024 for melanoma completing its first patient dosing in trials [2] - Bilibili-W (09626) rose by 2.78%, accumulating a total increase of about 25% over the past six days, with the new game "Three Kingdoms: Hundred Generals" set for testing in October [2] - LionTeng Holdings (02562) surged over 7% as it plans to acquire leading companies in artificial intelligence and blockchain to expand its digital finance layout [2] - GCL-Poly Energy (03800) rose by 3.97%, planning a discounted placement to raise approximately 5.392 billion HKD for structural adjustments in polysilicon capacity [2] - China General Nuclear Power Corporation Mining (01164) increased by 6.7%, as the U.S. seeks to expand its strategic uranium reserves, with institutions expecting a recovery in uranium prices [2] - Yunfeng Financial (00376) fell over 16% after announcing a discounted placement to raise about 1.15 billion HKD [2]

Market Overview - The Hang Seng Index rose by 0.07%, gaining 19 points to close at 26,465 points, while the Hang Seng Tech Index increased by 0.39% [1] - Early trading volume in Hong Kong stocks reached HKD 160.2 billion [1] Notable Stock Movements - New pharmaceutical stocks in the Hong Kong Stock Connect surged, with Yaojie Ankang-B (02617) rising over 49%, reaching a market capitalization of over HKD 240 billion [1] - Baize Medical (02609) saw an increase of over 76% [1] - Tongyuan Kang Pharmaceutical-B (02410) rose by over 36% [1] Specific Company Highlights - Fosen Pharmaceutical (01652) experienced a dramatic rise of over 410%, closing at HKD 1.35, up 297%, following the approval of Metformin and Ertugliflozin tablets [2] - Shanghai Fudan (01385) increased by 5.87%, with the company prepared for supply chain disruptions, and Morgan Stanley noted limited impact on demand [2] - SF Express (09699) rose by over 6% as its "SoFast" service launched in Macau, with positive revenue growth prospects according to Daiwa [2] - Valiant Pharmaceuticals-B (09887) increased by over 13%, completing the first medication trial for its core product LBL-024 for melanoma [2] - Bilibili-W (09626) rose by 2.78%, accumulating a 25% increase over six days, with the new game "Three Kingdoms: Hundred Generals" set for testing in October [2] - Liontech Holdings (02562) surged over 7% as it plans to acquire a leading AI and blockchain company to expand its digital finance footprint [2] - GCL-Poly Energy (03800) rose by 3.97%, planning a discounted share placement to raise approximately HKD 5.392 billion for structural adjustments in polysilicon capacity [2] - CGN Mining (01164) increased by 6.7% amid expectations of rising uranium prices as the U.S. seeks to expand its strategic uranium reserves [2] - Yunfeng Financial (00376) fell over 16% after announcing a discounted share placement to raise about HKD 1.15 billion [2]

Core Viewpoint - The article highlights significant movements in the Hong Kong and US stock markets, focusing on specific companies and their recent performance, driven by various strategic announcements and market conditions. Hong Kong Stock Market Summary - China General Nuclear Power Corporation (01164) rose over 6% following US Energy Secretary Chris Wright's suggestion to consider expanding strategic uranium reserves, indicating potential upward price adjustments for uranium [1] - Yunfeng Financial (00376) fell over 18% after announcing a rights issue at a discount of approximately 16.8%, aiming to raise about HKD 1.15 billion [1] - GCL-Poly Energy Holdings (03800) increased over 2% as it plans a rights issue at a discount of about 8.73%, targeting net proceeds of HKD 5.392 billion for structural adjustments in polysilicon production [1] - Lion Group Holding (02562) surged over 6% after signing a letter of intent to acquire a leading AI and blockchain company, expanding its digital finance footprint [1] - Pharmaron Beijing Co., Ltd. (02617) skyrocketed over 53% after being included in the Hong Kong Stock Connect list, with a cumulative increase of nearly 10 times since its inclusion, and northbound investors adding over HKD 300 million in two days [1] - Anta Sports Products (02020) rose over 2% as retail sales of sports goods showed rapid growth in the first eight months, indicating marginal improvement in sales [1] - SF Technology (09699) increased over 5% after launching its "SoFast" brand in Macau, marking a significant step in its overseas business expansion [1] - Shanghai Fudan (01385) rose over 6% as Morgan Stanley reported the company is well-prepared for supply chain disruptions, with limited demand impact expected [2] - Tianyue Advanced (02631) increased over 1% after being included in the Hong Kong Stock Connect, with silicon carbide expected to see new market growth [2] - Valiant Co., Ltd. (09887) rose over 10% after announcing the completion of the first patient dosing in a trial for its core product LBL-024 for melanoma [2] US Stock Market Summary - Tesla (TSLA.US) rose 3.56% as the head of its German factory announced an increase in production plans for Q3 and Q4 due to strong sales data [3] - NVIDIA (NVDA.US) fell 0.04% as it faces further investigation for violating antitrust laws [3] - Hesai Technology (HSAI.US) increased 4.31% after announcing a partnership with a leading US Robotaxi company, securing over USD 40 million in lidar orders [3] - XPeng Motors (XPEV.US) rose 2.20% after formalizing a deep cooperation with Magna Steyr in Austria, marking the start of local production in Europe [3] - NIO (NIO.US) increased 4.34% as it announced the NIO Day 2025 event, scheduled for September 20, where the new ES8 will be launched [3] - Apple (AAPL.US) rose 1.12% as Morgan Stanley reported that demand for the iPhone 17 series exceeded that of the previous year's iPhone 16 series during its first week of launch [4] - Fangdd Network Group (DUO.US) fell 9.17% following the National Bureau of Statistics' report indicating a decline in residential property prices in August [3] - Alibaba (BABA.US) rose 1.92% ahead of the 2025 Cloud Summit scheduled for September 24-26 in Hangzhou [4] - ASML Holding (ASML.US) increased 6.56% after announcing a EUR 1.3 billion investment in French AI startup Mistral AI, becoming its largest shareholder [4] - Bilibili (BILI.US) rose 6.40% as it announced the upcoming public test of its new strategy card game, "Three Kingdoms: Hundred Generals Card" [4] - Oracle (ORCL.US) increased 3.41% as management disclosed that its cloud infrastructure revenue is set to experience steep growth [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 本公司股東及潛在投資者於買賣本公司證券時務請審慎行事。 承董事會命 藥捷安康（南京）科技股份有限公司 TransThera Sciences (Nanjing), Inc. 藥捷安康（南京）科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2617） 自願性公告 股價及成交量的異常變動 本公告由藥捷安康（南京）科技股份有限公司（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發。 本公司董事會（「董事會」）注意到，本公司股份（「股份」）之交易價格及成交量近 期出現異常變動。經就本公司作出在有關情況下屬合理的一切查詢後，董事會確 認，概不知悉(i)導致股份出現該等股價及成交量異常變動之任何原因；或(ii)任何 須予公佈以避免股份出現虛假市場之資料；或(iii)根據上市規則第13.09(2)條及證 券及期貨條例（香港法例第571章）第XIVA部須予披露之任何內幕消息。 董事會亦確認 ...